Oxford Martin School

What are we doing?
We are studying the clinical effectiveness of charged particle therapy to treat cancer, and promoting its use in the UK and elsewhere.

Why is it important?
Radiotherapy successfully treats about 40% of cancers, but it can be an aggressive treatment, and limited in application if the cancer is too near a vital organ.  Particle therapy offers advantages over conventional radiotherapy, since a far lower dose is delivered to healthy tissues. Currently, there are few comprehensive reports on CPT efficacy and no formal clinical trials have been performed.

How are we different?
PTCRi is the result of a collaboration between a particle physicist and an oncologist. They have drawn together a team of researchers working on designing more effective particle accelerators to advance the technology for clinical use and building the robust clinical evidence base to promote charged particle therapy.